OmniAb (OABI) Stock Price, News & Analysis

Company Overview

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Key Stats

• Today's Range: $1.77 to $1.90
• 50-Day Range: $1.59 to $2.20
• 52-Week Range: $1.22 to $4.87
• Volume: 479,446 shs
• Average Volume: 496,098 shs
• Market Capitalization: $227.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.67
• Consensus Rating: Buy

OmniAb Stock Analysis - MarketRank™

OmniAb scored higher than 49% of companies evaluated by MarketBeat, and ranked 556th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

OmniAb has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

OmniAb has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OmniAb are expected to grow in the coming year, from ($0.61) to ($0.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OmniAb is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OmniAb is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

OmniAb has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.51% of the float of OmniAb has been sold short.

Short Interest Ratio / Days to Cover

OmniAb has a short interest ratio ("days to cover") of 9.8.

Change versus previous month

Short interest in OmniAb has recently decreased by 4.03%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OmniAb does not currently pay a dividend.

Dividend Growth

OmniAb does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.51% of the float of OmniAb has been sold short.

Short Interest Ratio / Days to Cover

OmniAb has a short interest ratio ("days to cover") of 9.8.

Change versus previous month

Short interest in OmniAb has recently decreased by 4.03%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for OABI on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added OmniAb to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OmniAb insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.60% of the stock of OmniAb is held by insiders.

Percentage Held by Institutions

72.08% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OABI Stock Analysis - Frequently Asked Questions

How have OABI shares performed this year?

OmniAb's stock was trading at $3.54 at the beginning of 2025. Since then, OABI shares have decreased by 47.7% and is now trading at $1.85.

How were OmniAb's earnings last quarter?

OmniAb, Inc. (NASDAQ:OABI) announced its earnings results on Wednesday, August, 6th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.01. The business earned $3.90 million during the quarter, compared to the consensus estimate of $5.33 million. OmniAb had a negative net margin of 275.83% and a negative trailing twelve-month return on equity of 22.79%.
Read the conference call transcript.

Who are OmniAb's major shareholders?

Top institutional shareholders of OmniAb include Private Management Group Inc. (2.09%), Geode Capital Management LLC (2.00%), Kent Lake PR LLC (1.43%) and Towerview LLC (0.68%). Insiders that own company stock include Matthew W Foehr, John L Higgins, Charles S Berkman, Kurt A Gustafson, Jennifer R Cochran and Steven Love.
View institutional ownership trends.

How do I buy shares of OmniAb?

Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OmniAb own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OmniAb investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 8/24/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:OABI
• CIK: 1846253
• Web: www.omniab.com
• Phone: 510-250-7800
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for OmniAb: $6.67
• High Price Target: $11.00
• Low Price Target: $3.00
• Potential Upside/Downside: +260.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$62.03 million
• Net Margins: -275.83%
• Pretax Margin: -296.89%
• Return on Equity: -22.79%
• Return on Assets: -20.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.77
• Quick Ratio: 3.77

Sales & Book Value

• Annual Sales: $23.03 million
• Price / Sales: 9.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.14 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 122,701,000
• Free Float: 112,149,000
• Market Cap: $227.00 million
• Optionable: Optionable
• Beta: 0.16